Antiviral therapy may not be enough to suppress genital herpes reactivation

Even high-dose antiherpetic therapy may not be enough to quell short bursts of subclinical genital herpes simplex virus (HSV) reactivation, which may account for the continued transmission of HSV despite suppressive antiviral therapy.

Researchers from the University of Washington, Seattle, United States, conducted 3 separate but complementary open-label crossover studies that compared standard-dose acyclovir (400 mg twice daily), standard-dose valacyclovir (500 mg daily), high-dose acyclovir (800 mg 3 times daily), high-dose valacyclovir (1 g 3 times daily), and no medication.

In all, 23,605 swabs were collected from 90 patients, of which 5.4% were HSV-positive and 80% were subclinical. The frequency of HSV shedding was significantly higher with no medication than with...

Log in or register for free to continue reading
Register Now For Free Already Registered? Log In
This entry was posted in Infectious Disease, Ob/Gyn, Pharmacology, Primary Care, Urology and tagged , , , , , , , , , , , , . Volume: .

Post a Comment

You must be logged in to post a comment.